Company Profile
ALK-Abelló A/S, an allergy solutions company develops treatments for respiratory allergy, anaphylaxis, and food allergy and new disease areas in the European Union, the United Kingdom, Norway, Switzerland, the United States, Canada, Japan, China, and globally. The company offers allergy immunotherapy products in the form of vaccines, injections, sublingual drops, and tablets for the treatment of various allergies
Including grass and tree pollen, house dust mites, ragweed, Japanese cedar, peanuts, and tree nuts. Its portfolio also includes adrenaline nasal sprays for emergency treatment of anaphylaxis and acute flares in chronic spontaneous urticaria, and ALK 014, a biologic for food allergies GRAZAX/GRASTEK, a tablet for grass pollen allergy.
Its portfolio also includes ACARIZAX, ODACTRA, and MITICURE/SENSIMUNE, which are tablets for house dust mite allergies, ITULAZAX/ITULATEK, a tablet for tree pollen allergy, RAGWITEK/RAGWIZAX, a tablet for ragweed pollen allergy, and CEDARCURE, a tablet for Japanese cedar pollen allergy.
Additionally, it offers consumer healthcare solutions, such as klarify.me, a digital patient engagement platform to help people manage their allergies allergen extracts for use in the diagnosis of specific allergies, such as skin prick and blood test
Emergency medicine treatment, such as adrenaline autoinjectors, an intra-muscular injection of adrenaline for the treatment of acute life-threatening allergic reactions including anaphylaxis.
The company has a collaboration with Torii Pharmaceutical Co., Ltd. for the development of GRAZAX and CEDARCURE; and Dr. Reddy's Laboratories for the development of Sensimune. Founded in 1923, ALK-Abelló is headquartered in Horsholm, Denmark.